Telix Pharmaceuticals (TLX) Stock Price, News & Analysis

Company Overview

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals and molecularly targeted radiation products. Its technologies are designed to help identify disease through medical imaging and, in some cases, deliver radiation directly to targeted cancer cells.

The company’s primary commercial product is Illuccix (kit for the preparation of gallium-68 gozetotide injection), a positron emission tomography imaging agent used to identify prostate-specific membrane antigen-positive lesions in adults with prostate cancer. Telix also has a pipeline of investigational imaging and therapeutic candidates targeting cancers and other serious diseases, including programs based on molecular targets such as carbonic anhydrase IX and prostate-specific membrane antigen.

Founded in 2015, Telix is headquartered in Melbourne, Australia, and serves healthcare markets internationally through operations and commercial activities in Australia, the United States, Europe and other regions. Christian Behrenbruch, a co-founder of the company, serves as Group Chief Executive Officer and Managing Director.

Key Stats

• Today's Range: $11.00 to $11.08
• 50-Day Range: $9.89 to $12.83
• 52-Week Range: $6.28 to $13.11
• Volume: 99,973 shs
• Average Volume: 226,579 shs
• Market Capitalization: $3.76 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $20.50
• Consensus Rating: Moderate Buy

Telix Pharmaceuticals Stock Analysis - MarketRank™

Telix Pharmaceuticals scored higher than 88% of companies evaluated by MarketBeat, and ranked 47th out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Telix Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Telix Pharmaceuticals has a consensus price target of $20.50, representing about 85.3% upside from its current price of $11.07.

Amount of Analyst Coverage

Telix Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 200.00%

Earnings Growth

Earnings for Telix Pharmaceuticals are expected to grow by 200.00% in the coming year, from $0.09 to $0.27 per share.

Price to Book Value per Share Ratio

Telix Pharmaceuticals has a P/B Ratio of 9.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.10% of the float of Telix Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Telix Pharmaceuticals has a short interest ratio ("days to cover") of 0.88, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Telix Pharmaceuticals has recently increased by 33.06%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Telix Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Telix Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: -0.13

News Sentiment

Telix Pharmaceuticals has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Telix Pharmaceuticals this week, compared to 9 articles on an average week.

Search Interest

8 people have searched for TLX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

4 people have added Telix Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Telix Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Institutions

Telix Pharmaceuticals has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 2/20/2026
• Today: 10/07/2026
• Investor Day 2026: 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TLX
• Previous Symbol: NASDAQ:TLX
• CIK: 2007191
• Web: www.telixpharma.com
• Phone: 61-3-9093-3855
• Fax: N/A
• Employees: 1,184
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Telix Pharmaceuticals: $20.50
• High Price Target: $22.00
• Low Price Target: $18.00
• Potential Upside/Downside: +85.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 1.16
• Current Ratio: 2.01
• Quick Ratio: 1.85

Sales & Book Value

• Annual Sales: $803.79 million
• Price / Sales: 4.66
• Cash Flow: $0.04 per share
• Price / Cash Flow: 258.04
• Book Value: $1.23 per share
• Price / Book: 8.97

Miscellaneous

• Outstanding Shares: 339,890,000
• Free Float: N/A
• Market Cap: $3.75 billion
• Optionable: N/A
• Beta: -0.17